134 related articles for article (PubMed ID: 18022380)
1. A time-resolved, internally quenched fluorescence assay to characterize inhibition of hepatitis C virus nonstructural protein 3-4A protease at low enzyme concentrations.
Mao SS; DiMuzio J; McHale C; Burlein C; Olsen D; Carroll SS
Anal Biochem; 2008 Feb; 373(1):1-8. PubMed ID: 18022380
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
Hamill P; Jean F
Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
[TBL] [Abstract][Full Text] [Related]
3. Establishment and application of high throughput screening model for hepatitis C virus NS3-4A protease inhibitors in vitro.
Jian-rui L; Yan-bin W; Shu-yi S; Hong-shan C; Jian-dong J; Zong-gen B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Feb; 33(1):98-101. PubMed ID: 21375947
[TBL] [Abstract][Full Text] [Related]
4. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
Geitmann M; Dahl G; Danielson UH
J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
[TBL] [Abstract][Full Text] [Related]
6. Longer wavelength fluorescence resonance energy transfer depsipeptide substrates for hepatitis C virus NS3 protease.
Konstantinidis AK; Richardson PL; Kurtz KA; Tripathi R; Chen CM; Huang P; Randolph J; Towne D; Donnelly J; Warrior U; Middleton T; Kati WM
Anal Biochem; 2007 Sep; 368(2):156-67. PubMed ID: 17644059
[TBL] [Abstract][Full Text] [Related]
7. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
Thomson JA; Perni RB
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
[TBL] [Abstract][Full Text] [Related]
9. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
Dahl G; Sandström A; Akerblom E; Danielson UH
Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
[TBL] [Abstract][Full Text] [Related]
10. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.
Umehara T; Fukuda K; Nishikawa F; Kohara M; Hasegawa T; Nishikawa S
J Biochem; 2005 Mar; 137(3):339-47. PubMed ID: 15809335
[TBL] [Abstract][Full Text] [Related]
11. [Detection of proteolytic activity of hepatitis C virus NS3-4A protease using enzymelinked immunosorbent assay].
Chen X; Guo J; Chen H; Wanglin
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Jun; 22(3):300-2. PubMed ID: 12903484
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput radiometric assay for hepatitis C virus NS3 protease.
Cerretani M; Di Renzo L; Serafini S; Vitelli A; Gennari N; Bianchi E; Pessi A; Urbani A; Colloca S; De Francesco R; Steinkühler C; Altamura S
Anal Biochem; 1999 Jan; 266(2):192-7. PubMed ID: 9888975
[TBL] [Abstract][Full Text] [Related]
13. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
14. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives.
Sudo K; Matsumoto Y; Matsushima M; Fujiwara M; Konno K; Shimotohno K; Shigeta S; Yokota T
Biochem Biophys Res Commun; 1997 Sep; 238(2):643-7. PubMed ID: 9299567
[TBL] [Abstract][Full Text] [Related]
15. A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates.
Taliani M; Bianchi E; Narjes F; Fossatelli M; Urbani A; Steinkühler C; De Francesco R; Pessi A
Anal Biochem; 1996 Aug; 240(1):60-7. PubMed ID: 8811880
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
Dahl G; Arenas OG; Danielson UH
Biochemistry; 2009 Dec; 48(48):11592-602. PubMed ID: 19839643
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Llinàs-Brunet M; Bailey MD; Bolger G; Brochu C; Faucher AM; Ferland JM; Garneau M; Ghiro E; Gorys V; Grand-Maître C; Halmos T; Lapeyre-Paquette N; Liard F; Poirier M; Rhéaume M; Tsantrizos YS; Lamarre D
J Med Chem; 2004 Mar; 47(7):1605-8. PubMed ID: 15027850
[TBL] [Abstract][Full Text] [Related]
18. HCV NS3 serine protease-neutralizing single-chain antibodies isolated by a novel genetic screen.
Gal-Tanamy M; Zemel R; Berdichevsky Y; Bachmatov L; Tur-Kaspa R; Benhar I
J Mol Biol; 2005 Apr; 347(5):991-1003. PubMed ID: 15784258
[TBL] [Abstract][Full Text] [Related]
19. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
